Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Drugs for Rare Diseases (DRD) Sub-Report offers credible, relevant insights related to DRD files to support a company’s reimbursement forecasting needs.
WHY DO YOU NEED THIS SUB-REPORT?
The CRaFT DRD Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the DRD public market reimbursement process – from HTA submission to provincial funding.
WHAT DOES THE REPORT INCLUDE?
This CRaFT DRD Sub-Report includes 30+ page of insights on DRD drugs reviewed by CADTH from 2017-2021 related to:
CADTH review volume & timeline
pCPA volume for initiated, completed, closed, and not-negotiated files
pCPA under-consideration and under-negotiation timeline
Funding volume & timeline for each jurisdiction
Timeline Comparison: DRD and Other Types of Files
Market access timeline forecasting (from HTA submission to first funding)
For further information on the content and pricing of CRaFT and the Drugs for Rare Diseases (DRD) Sub-report, please complete your contact information on our main CRaFT Report page.